Quoin Pharmaceuticals, Ltd. QNRX

QNRX Company Overview

Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases, with a primary emphasis on dermatological and genetic disorders. The company’s core strategy centers on identifying high unmet medical needs in niche patient populations and advancing targeted therapeutic candidates through clinical development. Quoin has concentrated much of its recent research and development activity on treatments for Netherton Syndrome, a rare inherited skin disorder characterized by severe skin barrier dysfunction and chronic inflammation.

The company evolved from broader specialty pharmaceutical operations into a rare disease-focused biotechnology platform following strategic restructuring and pipeline prioritization initiatives. Quoin is headquartered in Ashburn, Virginia, and operates as a development-stage biopharmaceutical organization without currently approved commercial products. Its revenue profile has historically been limited and primarily associated with financing activities rather than recurring product sales, which is consistent with many early-stage biotechnology companies pursuing regulatory approval pathways.